PR Newswire Clinical TrialsOriginal article
UTR Therapeutics Inc. Announces U.S. FDA Orphan Drug Designation and Rare Pediatric Disease Designation for UTRxMYCN M1-14
RegulatoryUTRxMYCN M1-14Positive
AI Analysis
Summary
UTR Therapeutics announced U.S. FDA Orphan Drug Designation and Rare Pediatric Disease Designation for UTRxMYCN M1-14, a therapeutic targeting MYCN in rare, aggressive soft tissue sarcomas. The dual designations recognize the drug's potential to address an unmet clinical need in pediatric and adult sarcoma patients.
Outcome Details
U.S. FDA Orphan Drug Designation and Rare Pediatric Disease Designation granted
Importance:6/10
Sentiment:
0.70
orphan drug designationrare pediatric disease designationMYCN targetingsoft tissue sarcomapediatric oncology
Read the original article
Published by PR Newswire Clinical Trials on September 29, 2026 4:21 PM